Login to Your Account

REMS a Plus?

Vivus Prepares to Roll Out Qsymia, Grow Obesity Market

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, August 13, 2012

After gaining FDA approval for its obesity drug Qsymia (phentermine/topiramate) last month, Vivus Inc. went to work preparing for a fourth-quarter launch of the drug. (See BioWorld Today July 19, 2012.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription